Tepotinib hydrochloride for the treatment of non-small cell lung cancer
Copyright 2021 Clarivate Analytics..
Non-small cell lung cancer (NSCLC) is one of the most devastating cancers with high mortality worldwide. By inhibiting the activity of specific molecular targets in the cancer cells, tyrosine kinase inhibitors (TKIs) have become a standard treatment in combating NSCLC. Tepotinib hydrochloride is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations. Tepotinib demonstrated durable clinical response in phase II clinical trials, which led to its approval for use in Japan and breakthrough therapy designation and accelerated approval in the U.S. These progresses highlighted tepotinib as a promising candidate for NSCLC patients. This review summarizes the pharmacological profile of tepotinib, preclinical studies and landmark clinical trials of tepotinib. In addition, we share our perspectives on the future direction of tepotinib as a novel anticancer drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 57(2021), 4 vom: 14. Apr., Seite 265-275 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Z-X [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2021 Date Revised 15.04.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2021.57.4.3238323 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324065191 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324065191 | ||
| 003 | DE-627 | ||
| 005 | 20231225185526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2021.57.4.3238323 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324065191 | ||
| 035 | |a (NLM)33851690 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Z-X |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tepotinib hydrochloride for the treatment of non-small cell lung cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2021 | ||
| 500 | |a Date Revised 15.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2021 Clarivate Analytics. | ||
| 520 | |a Non-small cell lung cancer (NSCLC) is one of the most devastating cancers with high mortality worldwide. By inhibiting the activity of specific molecular targets in the cancer cells, tyrosine kinase inhibitors (TKIs) have become a standard treatment in combating NSCLC. Tepotinib hydrochloride is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations. Tepotinib demonstrated durable clinical response in phase II clinical trials, which led to its approval for use in Japan and breakthrough therapy designation and accelerated approval in the U.S. These progresses highlighted tepotinib as a promising candidate for NSCLC patients. This review summarizes the pharmacological profile of tepotinib, preclinical studies and landmark clinical trials of tepotinib. In addition, we share our perspectives on the future direction of tepotinib as a novel anticancer drug | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Mesenchymal-epithelial transition (MET) inhibitors | |
| 650 | 4 | |a Non-small cell lung cancer (NSCLC) | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 4 | |a Tepotinib hydrochloride | |
| 650 | 4 | |a Tyrosine kinase inhibitors | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyridazines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a tepotinib |2 NLM | |
| 650 | 7 | |a 1IJV77EI07 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-met |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Li, J |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, S |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, L |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, C |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Z-S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 57(2021), 4 vom: 14. Apr., Seite 265-275 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2021 |g number:4 |g day:14 |g month:04 |g pages:265-275 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2021.57.4.3238323 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2021 |e 4 |b 14 |c 04 |h 265-275 | ||